Nuformix plc (LON:NFX – Get Free Report)’s stock price was up 5.9% during trading on Thursday . The stock traded as high as GBX 0.20 and last traded at GBX 0.18. Approximately 53,364,180 shares were traded during trading, an increase of 39% from the average daily volume of 38,471,695 shares. The stock had previously closed at GBX 0.17.
Nuformix Price Performance
The firm’s 50-day moving average price is GBX 0.18 and its 200 day moving average price is GBX 0.23. The company has a market capitalization of £4.41 million, a P/E ratio of -5.77 and a beta of 1.55.
Nuformix (LON:NFX – Get Free Report) last posted its earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
